These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32902128)

  • 1. Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
    Salahuddin T; Richardson V; McNeal DM; Henderson K; Hess PL; Raghavan S; Saxon DR; Valle JA; Waldo SW; Ho PM; Schwartz GG
    Diabetes Obes Metab; 2021 Jan; 23(1):97-105. PubMed ID: 32902128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
    Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1239-1248. PubMed ID: 37449993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [SGLT2 inhibitor or GLP-1 receptor agonist in a type 2 diabetic patient with cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2018 Aug; 14(615):1460-1465. PubMed ID: 30136462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.
    Knudsen JS; Baggesen LM; Lajer M; Nurkanovic L; Ustyugova A; Sørensen HT; Thomsen RW
    PLoS One; 2020; 15(3):e0229621. PubMed ID: 32130249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
    Dave CV; Kim SC; Goldfine AB; Glynn RJ; Tong A; Patorno E
    Circulation; 2021 Feb; 143(8):770-779. PubMed ID: 33302723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
    Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
    Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
    de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO
    Diabetes Obes Metab; 2024 Jul; 26(7):2787-2795. PubMed ID: 38618983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
    Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis.
    Ali MU; Mancini GBJ; Fitzpatrick-Lewis D; Connelly KA; O'Meara E; Zieroth S; Sherifali D
    Cardiovasc Diabetol; 2024 Feb; 23(1):72. PubMed ID: 38360604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2617-2629. PubMed ID: 38466894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Prescriptions of Cardioprotective Diabetic Agents After Coronary Artery Bypass Grafting Among U.S. Veterans.
    Deo SV; McAllister DA; Al-Kindi S; Elgudin Y; Chu D; Pell J; Sattar N
    Diabetes Care; 2022 Dec; 45(12):3054-3057. PubMed ID: 36256925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.
    Htoo PT; Buse J; Cavender M; Wang T; Pate V; Edwards J; Stürmer T
    J Am Heart Assoc; 2022 Feb; 11(4):e022376. PubMed ID: 35132865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose co-transporter 2 inhibitors & glucagon-like peptide-1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients.
    Mahmoud T; Yagan J; Hasan A; Gheith OA; Mostafa M; Rida S; El-Serwi N; Shaker M; Khalid M
    Clin Transplant; 2023 Dec; 37(12):e15144. PubMed ID: 37755118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
    Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.